Literature DB >> 22198664

Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.

Fang Chen1, Dongxue Wang, Xiaoming Shu, Ran Nakashima, Guochun Wang.   

Abstract

The aim of this study is to determine serum anti-melanoma differentiation-associated gene 5 prevalence and their clinical associations in Chinese patients with polymyositis and dermatomyositis (PM/DM). Serum anti-MDA5 antibody was detected by ELISA in 113 adult PM/DM patients and in various controls. Flow cytometry was applied to analyze the subgroups of lymphocytes in the peripheral blood of PM/DM patients. The serum anti-MDA5-positive rate in the DM patients (22.6%) was significantly higher compared with that in PM patients (0%, P < 0.005), patients with SLE (3.3%, P < 0.05), RA (3.3%, P < 0.05), pSS (0%, P < 0.05), pulmonary infection (0%, P < 0.05) and healthy controls (0%, P < 0.001). The percentage of decreased CD4(+), CD8(+) T cell counts, raised CD4(+)/CD8(+) ratio in peripheral blood and the incidence of acute/subacute interstitial pneumonia (A/SIP) were significantly higher in anti-MDA5-positive DM group than negative group (all P < 0.05). Additionally, logistic multivariate analysis showed that anti-MDA5 is an independent risk factor for death of ILD in DM (OR = 8.46, 95% CI 1.77-40.36, P = 0.007). In conclusion, in Chinese PM/DM patients, serum anti-MDA5 antibody is mainly presented in DM patients and can be a useful marker for A/SIP in patients with DM. It can predict unfavorable prognosis in DM patients with ILD. Further studies are needed to identify how the abnormal T cells in peripheral blood participated in the generation of the anti-MDA5 antibody.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198664     DOI: 10.1007/s00296-011-2323-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  26 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.

Authors:  Kei Hoshino; Yoshinao Muro; Kazumitsu Sugiura; Yasushi Tomita; Ran Nakashima; Tsuneyo Mimori
Journal:  Rheumatology (Oxford)       Date:  2010-05-25       Impact factor: 7.580

3.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

4.  Interstitial lung diseases associated with amyopathic dermatomyositis.

Authors:  T Suda; T Fujisawa; N Enomoto; Y Nakamura; N Inui; T Naito; D Hashimoto; J Sato; M Toyoshima; H Hashizume; K Chida
Journal:  Eur Respir J       Date:  2006-07-12       Impact factor: 16.671

5.  Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.

Authors:  Hideto Kameda; Hayato Nagasawa; Hiroe Ogawa; Naoya Sekiguchi; Hirofumi Takei; Michihide Tokuhira; Koichi Amano; Tsutomu Takeuchi
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

6.  Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes.

Authors:  Toshinobu Yokoyama; Teruo Sakamoto; Norihiko Shida; Masaharu Kinoshita; Yoshifumi Kunou; Ritsuko Karukaya; Manabu Takamatsu; Hisamichi Aizawa
Journal:  J Intensive Care Med       Date:  2005 May-Jun       Impact factor: 3.510

7.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

Review 8.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  Maryam Fathi; Ingrid E Lundberg
Journal:  Curr Opin Rheumatol       Date:  2005-11       Impact factor: 5.006

9.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

10.  Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.

Authors:  Hiroshi Mukae; Hiroshi Ishimoto; Noriho Sakamoto; Shintaro Hara; Tomoyuki Kakugawa; Seiko Nakayama; Yuji Ishimatsu; Atsushi Kawakami; Katsumi Eguchi; Shigeru Kohno
Journal:  Chest       Date:  2009-07-06       Impact factor: 9.410

View more
  29 in total

1.  Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.

Authors:  Lili Jiang; Youlian Wang; Qinglin Peng; Xiaoming Shu; Guochun Wang; Xiaomu Wu
Journal:  Clin Rheumatol       Date:  2019-02-09       Impact factor: 2.980

2.  Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.

Authors:  Yun Peng; Suhan Zhang; Yi Zhao; Yi Liu; Bing Yan
Journal:  Clin Rheumatol       Date:  2017-08-25       Impact factor: 2.980

Review 3.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 4.  Interstitial Pneumonia With Autoimmune Features: An Emerging Challenge at the Intersection of Rheumatology and Pulmonology.

Authors:  Erin M Wilfong; Robert J Lentz; Adam Guttentag; James J Tolle; Joyce E Johnson; Jonathan A Kropski; Peggy L Kendall; Timothy S Blackwell; Leslie J Crofford
Journal:  Arthritis Rheumatol       Date:  2018-10-27       Impact factor: 10.995

5.  Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.

Authors:  Kentaro Isoda; Takuya Kotani; Tohru Takeuchi; Takao Kiboshi; Kenichiro Hata; Takaaki Ishida; Kenichiro Otani; Takao Kamimori; Hiroshi Fujiwara; Takeshi Shoda; Shigeki Makino
Journal:  Rheumatol Int       Date:  2017-04-27       Impact factor: 2.631

6.  Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.

Authors:  Tomoya Sagawa; Takashi Kida; Tohru Inaba; Isao Yokota; Risa Sagawa; Akiko Kasahara; Shunya Kaneshita; Takuya Inoue; Hidetake Nagahara; Kazuki Fujioka; Makoto Wada; Masataka Kohno; Yutaka Kawahito
Journal:  Lung       Date:  2019-06-25       Impact factor: 2.584

7.  Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients.

Authors:  Lichong Shen; Qingran Yan; Xiaoxiang Chen
Journal:  Arch Rheumatol       Date:  2019-08-26       Impact factor: 1.472

8.  A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis.

Authors:  Q-L Peng; Y-M Zhang; L Liang; X Liu; L-F Ye; H-B Yang; L Zhang; X-M Shu; X Lu; G-C Wang
Journal:  Clin Exp Immunol       Date:  2019-12-18       Impact factor: 4.330

9.  Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Authors:  David F Fiorentino; Lorinda S Chung; Lisa Christopher-Stine; Lisa Zaba; Shufeng Li; Andrew L Mammen; Antony Rosen; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2013-11

Review 10.  Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Authors:  Robert W Hallowell; Julie J Paik
Journal:  Clin Exp Rheumatol       Date:  2021-03-25       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.